Porton(SZ:300363)2022-12-04 08:46Group 1: 2017 Performance Overview - The company's 2017 revenue is expected to decline by 0%-10%, while net profit attributable to shareholders is projected to decrease by 30%-40% due to significant fluctuations from two major clients [1] - Despite the revenue decline, sales growth from other clients helped maintain overall revenue stability in 2017 [1] - The profit decline is attributed to increased financial expenses, operating costs, and fixed asset depreciation [1] Group 2: 2018 Business Focus - In 2018, the company will focus on three key business areas: API projects, the Chinese market, and CRO services [2] - The company secured approximately 20 million in orders from Chinese clients in 2017 and anticipates further growth in this area due to increased domestic client visits [2] - Following the acquisition of J-STAR Research in 2017, the company plans to strengthen its CRO business and establish a J-STAR China division in Shanghai [2] Group 3: Future Plans and Strategies - The company is currently evaluating potential investors for its private placement, which is based on market price inquiries [3] - The CMO project for biopharmaceuticals is expected to launch in the first half of 2018, with a construction period of three years [3] - The introduction of China Merchants Capital as a strategic investor aims to stabilize shareholder reductions and improve the company's equity and governance structure [3] Group 4: Business Model and Strategy - The company aims to develop a "pharmaceutical service platform" strategy, focusing on both chemical and biological drugs [3] - Future plans include extending services from CMO to CRO, creating a comprehensive end-to-end service system [3]